Is OPKO Health Inc. (NASDAQ:OPK) about to enter sunset?


Here is an analysis at the scorecard of OPKO Health Inc. (NASDAQ:OPK) for the recent quarter and analyst projections for the coming periods.

The firm generated sales of 296.1M%, implying a jump of 0.02%% compared to a analogous quarter a year ago. The revenue growth increased/declined by grow%.

To achieve the recorded sales of 296.1M% for the quarter, the firm incurred $172.73M in cost of goods. Hence, after considering the cost of sales, OPKO Health Inc. came with a gross income of $123.37M.

Let?s look into the technical of the stock

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

OPKO Health Inc. incurred other expenses in the completion of operation. Taking those into account, it closed the quarter with EPS of $(0.06). The firm had 558.43M diluted outstanding shares at the close of the quarter.

For the next quarter, analysts on the average are projecting EPS of $-0.05.

OPKO Health Inc.’s cash balance at the close of the recent quarter was 131.05M%. The firm generated free cash flow of $(43.46M) during the quarter, while net operating cash flow was $(33.92M). Net change in cash was $(37.68M).

That said, OPKO Health Inc. closed the quarter with debt of 14.86M%. The debt increased/dropped by growing from the past period.

What is market thinking about OPKO Health Inc.? So far 6 analysts have assessed the stock, and they have average recommendation of Buy and average price target of $15.42. To put the recommendation into perspective, call in the range of 1.00 – 1.24 indicates a BUY recommendation, whereas 1.25 – 1.74 refers to OVERWEIGHT. HOLD recommendation is shown by 1.75 – 2.24, UNDERWEIGHT is signified by 2.25 – 2.74 while SELL is signified by 2.75 – 3.00.

Does OPKO Health Inc. have a strong balance sheet? A look at the firm’s balance sheet at the close of the most recent quarter displays that it has total assets of $2.76B, offset by total liabilities of $653.1M.

OPKO’s plans for expansion to 70 field based nephrology sales representatives is proceeding by expanding in selective geographic areas as reimbursement coverage is secured. More extensive formulary coverage across Medicare Part D and commercial plans and the larger sales force will support continuing growth of RAYALDEE and provide greater access for adults with secondary hyperparathyroidism (SHPT), with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.